Comparison 3. NGM 180‐215‐250 µg / EE 35 µg versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mean change in total lesion count at cycle 6	2	387	Mean Difference (IV, Fixed, 95% CI)	‐9.32 [‐14.19, ‐4.45]
2 Mean change in inflammatory lesion count at cycle 6	2	387	Mean Difference (IV, Fixed, 95% CI)	‐3.44 [‐5.43, ‐1.44]
3 Mean change in comedone count at cycle 6	2	387	Mean Difference (IV, Fixed, 95% CI)	‐5.81 [‐9.77, ‐1.85]
4 Clinician global assessment of improved acne at cycle 6	2	324	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.86 [2.31, 6.44]
5 Participant self‐assessment of improved acne at cycle 6	1	163	Peto Odds Ratio (Peto, Fixed, 95% CI)	4.50 [2.37, 8.56]
6 Discontinuation due to non‐acne adverse event	2	488	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.98 [0.91, 4.30]
7 Discontinuation due to worsening of acne	2	488	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.75 [0.75, 18.71]